SUMMARY Two randomised double blind, placebo controlled trials have been carried out to assess the effectiveness of nonathymulin, a synthetic thymic peptide hormone, in the treatment of rheumatoid arthritis (RA) and to compare three different dosage schedules (1, 5, and 10 mg/day). Nonathymulin 5 mg proved to be the most efficient dose, providing significant clinical improvement as evaluated by the global assessment of all patients who entered the trials (56% v 17% in the placebo group) (p<0.02) and by four objective parameters. This effect was accompanied with minimal adverse effects and was not associated with clear changes in immunological parameters. A significant correlation was observed, however, in clinical response to nonathymulin, and T cell subset imbalance was assessed using monoclonal anti-T cell antibodies and a functional suppressor T cell assay.
tism Association's criteria for definite or classic disease5 entered the studies after giving informed consent. Other criteria for entry were the presence of active disease defined by at least three of the following: erythrocyte sedimentation rate of 30 mm/h or higher, 60 minutes or more of morning stiffness, a Ritchie index6 of 10 or more, a Lee functional index7 of five or more, and at least three joints with effusion or synovitis. Corticosteroids and non-steroidal anti-inflammatory drugs or analgesics, or both, were maintained, and the drug dosages used by the patient during the trial were noted.
Patients with a serious concomitant medical illness judged to be in functional class IV by the criteria of the American Rheumatism Association8 or with a history of cancer, liver, or renal disease were excluded from the study. Patients were not accepted into the trial until slow acting antirheumatic drugs had been withdrawn for at least three months. During the study each patient remained under the care of the same investigator.
DESIGN OF STUDIES
Studies were double blind and of six months' duration. Patients and investigators remained unaware of drug assignments until each study was completed. Patients were randomly assigned to receive indistinguishable subcutaneous injections.
(Thy 1), nonathymulin 5 mg (Thy 5), or placebo were given each day for the first two weeks and then three times a week. In the second trial, injections of nonathymulin 10 mg (Thy 10) or placebo were given each day for six months. In both trials the placebo contained zinc sulphate at the same concentration as in the nonathymulin preparation (nonathymulin is a synthetic metallopeptide containing zinc). 3 9 CLINICAL ASSESSMENTS Each patient was examined by the same medical investigator every two months early in the morning. The clinical disease variables determined at each visit comprised (a) duration of morning stiffness, (b) grip strength (total in mmHg of three consecutive measurements on each side), (c) proximal interphalangeal circumference (total of 10 joints), (d) Ritchie index,6 (e) Lee functional index,7 (f) pain assessment (on 100 mm visual analogue scale), (g) two monthly assessment by patient of his or her own state compared with that at the previous examination (+3 = much better; +2 = better; +1 = slightly better; 0 = identical; -1 = slightly worse; -2 = worse; -3 = much worse), and (h) average of daily prednisone consumption in milligrams.
The overall assessment by the investigator and the patient at the end of the study was considered to be the main criterion. This overall assessment was evaluated on a scale of 0 = nil, 1 = mild, 2 = good, 3 = very good.
LABORATORY TESTS
Detailed blood counts including platelets count and the erythrocyte sedimentation rate were obtained every month. Serum creatinine and liver enzyme tests, including measurement of serum aspartate, alanine aminotransferase, alkaline phosphatase, and cholesterol, were measured every two months.
IMMUNOLOGICAL STUDIES
Immunological studies were performed at entry and on completion of the first trial.
Rheumatoid factor and antinuclear antibodies were studied according to conventional techniques.
Lymphocyte subsets were studied using the OKT series of monoclonal antibodies (OKT3 directed against all mature T cells, OKT4 directed against the helper/inducer subset, OKT8 directed against the suppressor/cytotoxic subset).10 The microscopic immunofluorescence technique used to evaluate the size of each T cell subset pool has already been described. " Suppressor activity of T 
Results

PATIENTS AND STUDY COURSE
In the first trial, of the 49 patients enrolled, 17 were initially assigned to receive placebo, 16 nonathymulin 1 mg, and 16 nonathymulin 5 mg. There were no significant differences at entry for demographic and RA variables among the three groups (Table 1) except for the immunological status of the patients. Normal T lymphocyte suppressor function was observed in 10 out of the 16 patients receiving nonathymulin 5 mg compared with only three out of the 16 receiving nonathymulin 1 mg, and four of the placebo group (p<0025). Five patients dropped out before the completion of the study. Two of these patients were receiving placebo; one was withdrawn after three days because of painful injections and the other because of inefficacy of treatment at month 4. One of the patients receiving nonathymulin 1 mg was withdrawn at month 4 because of treatment inefficacy. Two patients receiving nonathymulin 5 mg were withdrawn because of side effects; one developed peripheral thrombocytopenia at month 3 and the other showed vasculitis at month 5.
In the second trial, of the 30 patients enrolled, 15 were initially assigned to receive placebo and 15 to nonathymulin 10 mg. At entry there were no (44) 12 (6) 19 (8) 65 (26) 16 (7) 6 (5) (47) 11 (4) 16 (9) 65 (25) 12 (6) 6 (5) 13/16* * *p<0.01 (significance determined by the Mann-Whitney U test); tPIP = proximal interphalangeal.
'ND = not determined.
significant differences of demographic and RA variables between the two groups except for corticosteroid daily consumption, which was higher in the nonathymulin 10 mg group than in the placebo group (p<0-01) (see Table 1 ). Six patients withdrew before completion of the study: three in the placebo group (inefficacy at month 4) and three in the nonathymulin 10 mg group (adverse reaction at day 1 (one patient) and at month 1 (one patient); inefficacy at month 2 (one patient)).
All patients withdrawing from the studies were included in the global assessment analysis as a treatment failure (0 = nil), but they were excluded from the analysis of other clinical disease variables.
RESPONSE TO TREATMENT: GLOBAL ANALYSIS OF ALL PATIENTS WHO ENTERED THE TRIALS
The patient's expectation of benefit, i.e., personal assessment of response to treatment, was first considered in all patients who entered the first trial. The three groups differed significantly (p<002); moderate or major improvement was observed in 17-6% of patients receiving placebo compared with 62-5% of patients receiving nonathymulin 5 mg. The clinical improvement appeared to be better in patients receiving the higher nonathymulin dosage since a good or very good effect was observed in 37-5% of patients receiving nonathymulin 5 mg compared with only 12 5% of patients receiving nonathymulin 1 mg. Data in Table 2 show that the (80) 12 (5) 18 (5) 63 (23) 15 (6) 6 (6) T4 subsets (47 (9-9)) 41 (9)/-4 (11) 36 (12)/1 (9) 37 (10)/-4 (13) T8 subsets (30 (8.25)) H3H31 14 (5)/-0-2 (4) 13 (7)/0 3 (5) 16 (6)/-0-1 (8) T4/T8 ratio (1-7 (0-5)) 3 tp<O0E25. §Numbers at the start and the end of the trial.
receiving nonathymulin were withdrawn from the study because of side effects. A few minutes after the first injection one patient experienced a 'malaise' with low blood pressure, and laryngeal oedema, which resolved within 30 minutes after an intravenous corticosteroid injection. The second patient was withdrawn from the study at month 1 because of painful injections. It is worth noting that local painful injection occurred in nine of the patients in the first trial, resulting in withdrawal in one case, and in all the patients in the second trial, resulting in withdrawal in three. These painful injections were not only more frequent but also more severe in the second trial than in the first.
IMMUNOLOGICAL DATA (FIRST TRIAL) At the start of the trial T cell subsets were the same in the three groups, showing a clear cut increase in the OKT4+/T8+ ratio (>2.5) in 30-40% of patients (see Table 4 ). At variance, as stated above, the Table 5 ).
Moreover, seven of the eight patients showing clear clinical response had normal suppressor T cell function at entry, whereas this was the case in only six out of the 24 non-or poorly responsive patients (see Table 5 ), suggesting that a normal suppressive T cell activity in these experimental conditions might be a predictive criterion for the clinical response to nonathymulin treatment.
Discussion
These results suggest that nonathymulin is of benefit to patients suffering from well established rheumatoid arthritis (mean duration of the disease 13 years). The proportion of patients achieving moderate or very good overall improvement is higher in patients receiving nonathymulin than in patients receiving placebo. The difference reaches significance in the first trial (p<002). Statistically significant differences are also noted for several important individual parameters (grip strength, Lee index). It is important to stress the significant though modest effect on steroid consumption since one may assume that the other effects of nonathymulin have been partly blurred by the decrease of steroid dosage in patients showing clinical improvement. The analysis of the second trial is complicated by the difference in daily corticosteroid consumption noted between the two groups at the start of the trial and by the small number of patients included in the study. In the two trials the approximate 90% confidence interval for the difference in true response probabilities favours nonathymulin. The clinical improvement was more clear cut when using nonathymulin 5 mg rather than nonathymulin 1 mg three times a week. At variance, the rate of improvement was not further increased by using nonathymulin at 10 mg a day, suggesting that the dosage of 5 mg three times a week is sufficient for optimal effect. One cannot exclude the possibility that giving the compound more frequently would not be more efficient. This hypothesis would be in keeping with the relatively short half life of nonathymulin (30-60 min), even if the duration of the drug effect on T lymphocytes is much longer (24-48 h3).
Minor side effects were noted. Local pain was common at 10 mg and was probably due to the zinc salts since it was also observed with the placebo preparation containing zinc. It was rare in the other groups. Thrombocytopenia and vasculitis were observed in two cases of the 5 mg group. They probably represented complications of the disease rather than an adverse drug reaction since they recurred long after treatment cessation. The malaise noted in one case (10 mg/day) after the first injection is more difficult to interpret. An allergic reaction is unlikely because of the small molecular weight of the peptide. It should be noted that such a reaction has never been observed in more than 150 other patients treated with nonathymulin (unpublished data).
The potential clinical benefit of nonathymulin in RA is obviously linked to its low toxicity compared with that of other drugs that often appear more efficient than the peptide but are also more toxic (e.g., D-penicillamine,'4 triopronin,'5 gold salts). 
